它通过与HER2的细胞外结构域IV结合,抑制HER2信号通路,阻止细胞周期进程,并介导抗体依赖性细胞毒性作用(ADCC),从而杀死癌细胞。曲妥珠单抗可用于HER2过表达乳腺癌的辅助治疗、新辅助治疗以及晚期转移性乳腺癌的治疗。 帕妥珠单抗(Pertuzumab,Perjeta):...
2019年2月28日,Herceptin Hylecta(曲妥珠单抗/透明质酸酶)获得美国食品药品监督管理局(FDA)批准上市,用于治疗成人HER2过表达的转移性乳腺癌。 曲妥珠单抗透明质酸酶 2、帕妥珠单抗(Perjeta) 帕妥珠单抗(Perjeta)是诺华公司研发的一种重组人源化单克隆抗体,于2012年获得美国食品药品监督管理局FDA批准上市,帕妥珠单抗...
根据美国国立综合癌症网络乳腺癌临床实践指南,HER2阳性复发/转移性乳腺癌患者的标准一线治疗方案是帕妥珠单抗(Perjeta)联合曲妥珠单抗(Herceptin)和多西他赛。这一联合方案于2012年基于3期CLEOPATRA试验(NCT00567190)的结果获批用于该适应症。在该试验中,接受帕妥珠单抗联合曲妥珠单抗和多西他赛治疗的患者(n = 343)ORR达到...
[9].Bellon, J.R., et al., Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat, 2019. 176(...
the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) at high risk of recurrence Metastatic Breast Cancer PERJETA® (pertuzumab) is indicated for use in combination with Herceptin® (trastuzumab) and docetaxel for the treatment of patients with HER2-positive metastatic bre...
Patients receive a taxane with trastuzumab (Herceptin) and pertuzumab (Perjeta; HP) and if they achieve a pCR, then they can continue on trastuzumab/pertuzumab in the adjuvant setting with no further need for chemotherapy. However, if they have residual disease, they can escalate therapy. In ...
Herceptin (trastuzumab) is a monoclonal antibody drug used to prevent the recurrence of/and or treatment of breast cancer that has spread beyond the breast. There is a black box warning for Herceptin warning of the possibility of heart failure in some pa
在手术后,患者继续接受辅助设置中的和直至在研究期间施用总共17个周期的和直至手术后2周不应开始辅助和治疗。如果第一剂辅助perjeta和herceptin和最后一剂新辅助和之间的间隔超过6周的话,需要重新加载剂量840mg的和8mg/kg的会在60(±10)分钟里施用初始剂量的而且会进一步对患者观察60分钟。如果患者经历输注相关症状...
Abnormal alterations in human epidermal growth factor receptor 2 (HER2, neu, and erbB2) are associated with the development of many tumors. It is currently a crucial treatment for multiple cancers. Advanced in molecular biology and further exploration of
In May 2022, the FDA approved trastuzumab deruxtecan for use in patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti–HER2-based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence du...